top of page

What's happening at AdRegeneer?


AdRegeneer at Curious2024 – Future Insight e.V. Conference


We are happy to participate in the Curious2024 – Future Insight e.V. Conference. It was an incredible event, and we enjoyed connecting and sharing our innovations with so many creative and inspiring minds.

AdRegeneer Named Finalist for GlobalCall24


AdRegeneer is proud to announce our selection as a finalist for the GlobalCall24 in the Science Startups category by the Falling Walls Foundation. We look forward to the next steps and our participation in the Science Summit 2024 in Berlin. Congratulations to all the finalists!


Approval for Innosuisse Initial Coaching Programme!


We are excited to announce that AdRegeneer has been approved for the prestigious Innosuisse Initial Coaching programme. We look forward to collobarote closely with Innosuisse.

Adregeneer Successfully Passed Scientific Advice Meeting with BfArM


Adregeneer has reached a pivotal milestone in its clinical development journey by successfully passing the Scientific Advice Meeting with the Federal Institute for Drugs and Medical Devices (BfArM).  With the green light from BfArM, Adregeneer is now primed to advance its Phase I and Phase II clinical trial plans towards the next stages of development.

Medical form with stethoscope

Patent granted!

Patent Preparation and Prosecution


We are thrilled to announce that one of our key patent applications has been granted in the United States! This milestone marks a significant step forward in our commitment to innovation and advancing regenerative medicine

W.A. de Vigier Award 2024


Exciting news! Our startup has been chosen as one of the Top 50 finalists for the prestigious W.A. de Vigier Award 2024, recognizing our innovation and potential in the entrepreneurial landscape.

Link for the pitch


Neue Zürcher Zeitung!



 Our groundbreaking work has been shared by the prestigious Swiss newspaper Neue Zürcher Zeitung! 

Press release

Fördern & Stiften Newsletter of JGU


Our co-founder Prof. Jacob's research on nervous system regeneration has shown promising results, including the identification of a protein that controls the activation of genes necessary for myelin rebuilding after damage. Professor Jacob's work, supported by the  Mainzer Wissenschaftsstiftung and other generous supporters, has the potential to lead to significant advances in the treatment of MS and other neurological disorders.

Press release


Frankfurter Allgemeine Zeitung


In the ever-evolving landscape of scientific discovery, we are thrilled to share that our work, featured in the prestigious Frankfurter Allgemeine Zeitung, has uncovered a breakthrough in the field of neurodegenerative diseases, particularly multiple sclerosis (MS) and nerve injuries.

Press release



We are happy to announce that AdRegeneer has been accepted to join Batch #14 of XPRENEUR's three-month incubation program!


Healthcare Hackathon 2023


AdRegeneer received the 3rd prize at the Healthcare Hackathon 2023. This was our 1st pitch in presence and 2nd pitch overall!

Collection of Trophies

New Publication


Remyelinated spinal cord.tif

Discover our new publication in Nature Communications! In this article, we elucidate a major mechanism that controls myelination and remyelination after lesion and we identify a treatment that promotes remyelination in the peripheral and central nervous systems after traumatic or demyelinating lesions.


Press release

Podcast with Nele Handwerker: in English and in German

Prof. Jacob receives the IRP Schellenberg Research Prize


Neurobiologist Prof. Dr. Claire Jacob has been awarded the IRP Schellenberg Research Prize. The International Foundation for Research in Paraplegia (IRP) awards this prize every two years to exceptional researchers in the field of paraplegia. This year, the award, which comes with a prize of 100,000 Swiss Francs, was split equally between Prof. Dr. Claire Jacob and neurobiologist Prof. Dr. Magdalena Götz from the Helmholtz Zentrum München.

bottom of page